FX1产品是FX1 is a potent B cell lymphoma 6 (BCL6) inhibitor. FX1 displays 10-fold greater potency than endogenous corepressors and binds an essential region of the BCL6 lateral groove. FX1 disrupts formation of the BCL6 repression complex, reactivated BCL6 target genes, and mimics the phenotype of mice engineered to express BCL6 with corepressor binding site mutations.